Choosing the right first chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized approach to selecting your first chemotherapy based on tumor gene activity. It aims to match treatment to your cancer’s biology to improve outcomes for people with advanced (metastatic) pancreatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed pancreatic ductal adenocarcinoma diagnosed by biopsy or fluid test
- Your cancer has spread to other parts of the body (metastatic disease)
- You have a measurable or trackable tumor spot on scans
- You are starting first-line (no prior chemotherapy for pancreatic cancer is allowed)
- You can provide tumor tissue from your pancreas tumor or liver metastasis for testing
- Your general health markers from recent blood tests and scans are adequate, and you should be well enough to do study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) is effective as a first treatment for pancreatic cancer that has spread. It also studies how gut bacteria affect the success of a second treatment with gemcitabine and paclitaxel. The goal is to find better ways to treat pancreatic cancer by personalizing therapy.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
Hear when a new Prognosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.